The 2022 cancer survivorship statistics report highlights the growing number of cancer survivors in the United States, with over 18 million Americans alive with a history of cancer as of January 1, 2022. The most prevalent cancers among males are prostate, melanoma, and colon/rectum, while among females, they are breast, uterine corpus, and thyroid. Over half of survivors were diagnosed within the last 10 years, and two-thirds are aged 65 or older. Significant racial disparities exist in treatment access, particularly for rectal cancer, where Black patients are less likely to receive surgery compared to White patients. These disparities are exacerbated by lower rates of early-stage diagnosis among Black patients for most cancers. The report details treatment patterns for the most common cancers, including breast, colon/rectum, leukemias, lymphomas, lung, and melanoma. For breast cancer, over 4 million women are living with a history of invasive breast cancer, with a significant portion of survivors receiving metastatic disease. Treatment options vary, with breast-conserving surgery and adjuvant radiation being common for early-stage disease, while mastectomy is more frequent for advanced stages. Black women are less likely to receive breast-conserving surgery and more likely to receive only chemotherapy. Survival rates for Black women are lower than for White women, with the largest disparities in advanced stages. For colon and rectal cancer, over 1.4 million people are living with a history of the disease, with a majority aged 65 or older. Treatment for stage I and II colon cancer typically involves surgery without chemotherapy, while stage III patients often receive adjuvant chemotherapy. Racial disparities in treatment access are significant, with Black patients less likely to receive surgery for early-stage rectal cancer. Survival rates have improved over time, largely due to advances in detection and treatment. In lung cancer, over 654,000 people are living with a history of the disease, with a majority aged 65 or older. Treatment options vary by stage, with surgery being common for early-stage disease and chemotherapy and radiation for advanced stages. Racial disparities in treatment access are significant, with Black patients less likely to receive surgery compared to White patients. Survival rates have improved over time, but most cases are diagnosed at advanced stages. For melanoma, over 1.5 million people are living with a history of the disease, with a majority younger than 65. Surgery is the primary treatment, with adjuvant immunotherapy and targeted therapy being common for advanced stages. Survival rates have improved significantly, largely due to increased detection of early-stage disease and advances in treatment. The report emphasizes the importance of addressing racial disparities in cancer treatment and survivorship, as well as the need for equitable access to available resources to optimize care for cancer survivors. It also highlights the long-term health effects of cancer treatment, including physical, cognitiveThe 2022 cancer survivorship statistics report highlights the growing number of cancer survivors in the United States, with over 18 million Americans alive with a history of cancer as of January 1, 2022. The most prevalent cancers among males are prostate, melanoma, and colon/rectum, while among females, they are breast, uterine corpus, and thyroid. Over half of survivors were diagnosed within the last 10 years, and two-thirds are aged 65 or older. Significant racial disparities exist in treatment access, particularly for rectal cancer, where Black patients are less likely to receive surgery compared to White patients. These disparities are exacerbated by lower rates of early-stage diagnosis among Black patients for most cancers. The report details treatment patterns for the most common cancers, including breast, colon/rectum, leukemias, lymphomas, lung, and melanoma. For breast cancer, over 4 million women are living with a history of invasive breast cancer, with a significant portion of survivors receiving metastatic disease. Treatment options vary, with breast-conserving surgery and adjuvant radiation being common for early-stage disease, while mastectomy is more frequent for advanced stages. Black women are less likely to receive breast-conserving surgery and more likely to receive only chemotherapy. Survival rates for Black women are lower than for White women, with the largest disparities in advanced stages. For colon and rectal cancer, over 1.4 million people are living with a history of the disease, with a majority aged 65 or older. Treatment for stage I and II colon cancer typically involves surgery without chemotherapy, while stage III patients often receive adjuvant chemotherapy. Racial disparities in treatment access are significant, with Black patients less likely to receive surgery for early-stage rectal cancer. Survival rates have improved over time, largely due to advances in detection and treatment. In lung cancer, over 654,000 people are living with a history of the disease, with a majority aged 65 or older. Treatment options vary by stage, with surgery being common for early-stage disease and chemotherapy and radiation for advanced stages. Racial disparities in treatment access are significant, with Black patients less likely to receive surgery compared to White patients. Survival rates have improved over time, but most cases are diagnosed at advanced stages. For melanoma, over 1.5 million people are living with a history of the disease, with a majority younger than 65. Surgery is the primary treatment, with adjuvant immunotherapy and targeted therapy being common for advanced stages. Survival rates have improved significantly, largely due to increased detection of early-stage disease and advances in treatment. The report emphasizes the importance of addressing racial disparities in cancer treatment and survivorship, as well as the need for equitable access to available resources to optimize care for cancer survivors. It also highlights the long-term health effects of cancer treatment, including physical, cognitive